Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charlie Gourley

Showing results (11-20 of 145) with videos related to

Pageof 15
Sort By:
Gynecologic Oncology|December 17, 2013
Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implicationsXue Xiao, David W Melton, Charlie Gourley
Oncotargets and Therapy|May 27, 2017
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerRobert L Hollis, Michael Churchman, Charlie Gourley
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian CancerCharlie Gourley, Joan L Walker, Helen J Mackay
Lancet (London, England)|March 27, 2019
Epithelial ovarian cancerStephanie Lheureux, Charlie Gourley, Ignace Vergote, et al.
Expert Review of Anticancer Therapy|December 15, 2016
Endocrine therapy in epithelial ovarian cancerSimon P Langdon, Charlie Gourley, Hani Gabra, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 9, 2025
Controversies in the management of serous borderline tumors and low-grade serous ovarian cancerNarthana Ilenkovan, Neil Ryan, Patricia Roxburgh, et al.
The Cochrane Database of Systematic Reviews|September 9, 2010
Interventions for the treatment of borderline ovarian tumoursOlusola Faluyi, Melanie Mackean, Charlie Gourley, et al.
Cancers|June 26, 2020
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian CancerSimon P Langdon, C Simon Herrington, Robert L Hollis, et al.
Plos One|August 8, 2013
Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatinStephanie Morgan, Federica Lopes, Charlie Gourley, et al.
Current Opinion in Oncology|August 16, 2020
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?Charlie Gourley, Rowan E Miller, Robert L Hollis, et al.
Pageof 15

Showing results (11-20 of 145) with videos related to

Sort By:
Pageof 15
Gynecologic Oncology|December 17, 2013
Mismatch repair deficiency in ovarian cancer -- molecular characteristics and clinical implicationsXue Xiao, David W Melton, Charlie Gourley
Oncotargets and Therapy|May 27, 2017
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerRobert L Hollis, Michael Churchman, Charlie Gourley
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian CancerCharlie Gourley, Joan L Walker, Helen J Mackay
Lancet (London, England)|March 27, 2019
Epithelial ovarian cancerStephanie Lheureux, Charlie Gourley, Ignace Vergote, et al.
Expert Review of Anticancer Therapy|December 15, 2016
Endocrine therapy in epithelial ovarian cancerSimon P Langdon, Charlie Gourley, Hani Gabra, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 9, 2025
Controversies in the management of serous borderline tumors and low-grade serous ovarian cancerNarthana Ilenkovan, Neil Ryan, Patricia Roxburgh, et al.
The Cochrane Database of Systematic Reviews|September 9, 2010
Interventions for the treatment of borderline ovarian tumoursOlusola Faluyi, Melanie Mackean, Charlie Gourley, et al.
Cancers|June 26, 2020
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian CancerSimon P Langdon, C Simon Herrington, Robert L Hollis, et al.
Plos One|August 8, 2013
Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatinStephanie Morgan, Federica Lopes, Charlie Gourley, et al.
Current Opinion in Oncology|August 16, 2020
Role of Poly (ADP-Ribose) Polymerase inhibitors beyond BReast CAncer Gene-mutated ovarian tumours: definition of homologous recombination deficiency?Charlie Gourley, Rowan E Miller, Robert L Hollis, et al.
Pageof 15